Atorvastatin News and Research

RSS
BHD launches Statin Induced Myopathy Genotype test

BHD launches Statin Induced Myopathy Genotype test

Mylan introduces Atorvastatin Calcium in France, Belgium, UK, Ireland and the Netherlands

Mylan introduces Atorvastatin Calcium in France, Belgium, UK, Ireland and the Netherlands

Resverlogix completes RVX-208 Phase 2b trial on CVD

Resverlogix completes RVX-208 Phase 2b trial on CVD

Watson first quarter net income increases 87% to $208.8 million

Watson first quarter net income increases 87% to $208.8 million

Discontinuance of statin therapy increases CVD mortality risk in RA patients

Discontinuance of statin therapy increases CVD mortality risk in RA patients

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

SAR236553/REGN727 antibody reduces LDL by up to 72% in patients

SAR236553/REGN727 antibody reduces LDL by up to 72% in patients

ETC-1002 drug reduces LDL cholesterol levels in hypercholesterolemic patients

ETC-1002 drug reduces LDL cholesterol levels in hypercholesterolemic patients

Positive results from Amgen's AMG 145 Phase 1b study on patients with LDL-C

Positive results from Amgen's AMG 145 Phase 1b study on patients with LDL-C

New cholesterol lowering drugs on the horizon

New cholesterol lowering drugs on the horizon

Merck fails to get FDA nod for new cholesterol lowering combo pill

Merck fails to get FDA nod for new cholesterol lowering combo pill

Making a medicinewise choice between brands

Making a medicinewise choice between brands

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron reports total revenues of $123.0M for fourth quarter 2011

FDA grants Mylan tentative approval for Atorvastatin Calcium ANDA

FDA grants Mylan tentative approval for Atorvastatin Calcium ANDA

Cost paid for statins 400% higher in the U.S. than U.K.

Cost paid for statins 400% higher in the U.S. than U.K.

Veloxis, Athena partner to establish competitive presence for AtorFen in emerging markets

Veloxis, Athena partner to establish competitive presence for AtorFen in emerging markets

Ranbaxy signs consent decree with U.S. FDA

Ranbaxy signs consent decree with U.S. FDA

Viewpoints: Politics overtakes Plan B; Gingrich's entitlement plans; Cheeseburgers and death

Viewpoints: Politics overtakes Plan B; Gingrich's entitlement plans; Cheeseburgers and death

Ranbaxy introduces Atorvastatin-Amlodipine besylate tablets in the U.S.

Ranbaxy introduces Atorvastatin-Amlodipine besylate tablets in the U.S.

Ranbaxy receives FDA approval to manufacture and market generic Lipitor

Ranbaxy receives FDA approval to manufacture and market generic Lipitor